Stock Price
29.14
Daily Change
0.73 2.57%
Monthly
19.87%
Yearly
-31.93%
Q3 Forecast
28.51



Peers Price Chg Day Year Date
Terumo 2,620.00 -52.50 -1.96% -6.04% Aug/17
Abbott 111.25 -0.02 -0.02% -15.56% Aug/14
AngioDynamics 15.85 0.19 1.21% 80.73% Aug/14
Accuray 0.28 0.003 0.91% -80.14% Aug/14
AtriCure 44.30 0.81 1.86% 24.96% Aug/14
Baxter International 26.73 -0.32 -1.18% 10.55% Aug/14
Becton, Dickinson and Co. 183.40 1.43 0.79% -6.40% Aug/14
Boston Scientific 51.83 0.14 0.27% -49.76% Aug/14
Artivion 29.14 0.73 2.57% -31.93% Aug/14
Edwards Lifesciences 91.60 -0.96 -1.04% 17.05% Aug/14

Indexes Price Day Year Date
US2000 3068 15.57 0.51% 34.20% Aug/14

Artivion Inc traded at $29.14 this Friday August 14th, increasing $0.73 or 2.57 percent since the previous trading session. Looking back, over the last four weeks, Artivion gained 19.87 percent. Over the last 12 months, its price fell by 31.93 percent. Looking ahead, we forecast Artivion Inc to be priced at 28.51 by the end of this quarter and at 26.71 in one year, according to Trading Economics global macro models projections and analysts expectations.

CryoLife, Inc. (CryoLife), is a medical device company. The Company is engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as Surgical Sealants, BioGlue products, JOTEC products, On-X products, CardioGenesis cardiac laser therapy, PhotoFix, and NEXUS. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues.